Home / ABC plant

FDF / DRUG PRODUCTS in Europe

Oral forms (liquid & solid)

Italy Europe

FDF / DRUG PRODUCTS in Europe

Oral forms (liquid & solid)

FDF / DRUG PRODUCTS  in Europe

About the plant

ABC Plant is located in Ivrea, Northern Italy, between Turin and Milan. It was originally built in 1990 and was acquired by ABC in the 2000s. ABC specializes in the development and manufacturing of pharmaceutical products in solid and liquid oral forms. The company is authorized to handle controlled substances. Listed below are the finished dosage forms managed by ABC:

  • Granules

  • Capsules (immediate release, sustained release, filled with mini-tabs/pellets)

  • Tablets (coated, uncoated)

  • Syrups and suspensions

  • Mono-dose vials with caps

  • Oral drops

The plant occupies a total area of 76,000 square meters, with 30,000 square meters currently covered.
ABC is currently expanding the covered area with a new warehouse and an additional 1,000 square meters of pharmaceutical-grade space to accommodate new equipment (fluid bed granulator) dedicated to the production of solid oral forms.

ABC continues to invest in maintaining its production site at the forefront and supporting the growth of its customers and business.
ABC is also available to evaluate dedicating new areas to specific production requests from its clients.

ABC is the right partner to rely on to secure your business!


Certifications
  • ISO
  • EMA (EU GMP)
  • World Health Organization (GMP / HACCP)

Activity
  • Oral liquids and semisolids, Oral solids / OSD, Bottles, Ampoules, Oral solutions, Oral suspensions, Syrups, Tablets, Hard capsules, Granules / Pellets, Powders, FDF / DRUG PRODUCTS manufacturing

Features
  • Uses: Investigational, Commercial (Phase IV), Preclinical, Phase I, Phase II, Phase III, Human
  • Toxicity (OEB classification): N/A
  • DEA: Schedule I (high potential for abuse / no medical use), Schedule II (high potential for abuse / medical use), Schedule III (lower potential for abuse), Schedule IV (low potential for abuse), Schedule V (lowest potential for abuse)
  • BSL: N/A
  • Therapeutic areas: (A) Digestive tract and metabolism, (C) Cardiovascular system, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system
  • Markets: EMA (EU), MHRA (UK), MFDS (South Korea), Russian Health Authorities

Batch Size / Reactor
  • Small, Medium, Large

Services
  • Development services, Manufacturing services, Preformulation studies, R&D, Process development, Process optimization, Process validation, Stability studies execution, ICH Stability studies, Tech transfer, Pilot plant, Formulation mixing, Engineering batches, Scale-up, Pilot batches, Registration batches, Batch records

Contact us

If you have any questions or suggestions, click here. We will be happy to assist you.

Want to see all the information?

Unleash the full power of MAI CDMO

Register for free

Grifols
Salvat
Liof Pharma
VIVUNT
Ascil
Shilpa Biologicals